| Lung Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.92 |
| Non-Small Cell Lung Cancer |
0 |
0.71 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.6 |
| Small Cell Lung Cancer |
0 |
0.56 |
| Cancer |
0 |
0.49 |
| Europe |
0 |
0.43 |
| Lung |
0 |
0.43 |
| Follicular Lymphoma |
0 |
0.39 |
| Lymphoma |
0 |
0.37 |
| Blood |
0 |
0.18 |
| Food and Drug Administration (FDA) |
0 |
0.18 |
| Grant |
0 |
0.18 |
| Refractory |
0 |
0.18 |
| Patient Safety |
0 |
0.15 |
| Adverse Effects |
0 |
0.12 |
| Fever |
0 |
0.12 |
| Infectious Mononucleosis |
0 |
0.1 |
| Peripheral Edema |
0 |
0.09 |
| Headache |
0 |
0.07 |
| Herpes Simplex |
0 |
0.07 |
| Neutropenia |
0 |
0.07 |
| Chemotherapy |
0 |
0.06 |
| Cytokines |
0 |
0.06 |
| Dyspnea |
0 |
0.06 |
| Edema |
0 |
0.06 |
| Fatigue |
0 |
0.06 |
| Hypophosphatemia |
0 |
0.06 |
| Immunotherapy |
0 |
0.06 |
| Nausea |
0 |
0.06 |
| Platinum |
0 |
0.06 |
| T-Lymphocyte |
0 |
0.06 |
| Tyrosine Kinase |
0 |
0.06 |